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Bordetella avium is the causative agent of bordetellosis, which remains to be the cause
of severe losses in the turkey industry. Given the lack of vaccines that can provide
good protection, developing a novel vaccine against B. avium infection is crucial. In
this study, we constructed a eukaryotic expression plasmid, which expressed the outer
membrane protein A (ompA) of B. avium, to prepare a B. avium recombinant ompA-
DNA vaccine. Three concentrations (low, middle, and high) of Taishan Pinus massoniana
pollen polysaccharides (TPPPS), a known immunomodulator, were used as adjuvants,
and their immune conditioning effects on the developed DNA vaccine were examined.
The pure ompA-DNA vaccine, Freund’s incomplete adjuvant ompA-DNA vaccine, and
the empty plasmid served as the controls. The chickens in each group were separately
inoculated with these vaccines three times at 1, 7, and 14 days old. Dynamic changes in
antibody production, cytokine secretion, and lymphocyte count were then determined
from 7 to 49 days after the first inoculation. Protective rates of the vaccines were
also determined after the third inoculation. Results showed that the pure DNA vaccine
obviously induced the production of antibodies, the secretion of cytokines, and the
increase in CD4+ and CD8+ T lymphocyte counts in peripheral blood, as well as
provided a protective rate of 50% to the B. avium-challenged chickens. The chickens
inoculated with the TPPPS adjuvant ompA-DNA vaccine and Freund’s adjuvant ompA-
DNA vaccine demonstrated higher levels of immune responses than those inoculated
with pure ompA-DNA vaccine, whereas only the ompA-DNA vaccine with 200 mg/mL
TPPPS completely protected the chickens against B. avium infection. These findings
indicate that the B. avium ompA-DNA vaccine combined with TPPPS is a potentially
effective B. avium vaccine.
Keywords: Bordetella avium, outer membrane protein A, DNA vaccine, Pinusmassoniana pollen polysaccharides,
adjuvant, chicken
INTRODUCTION
Bordetella avium was ﬁrst isolated from the respiratory tracts of turkeys in 1967 (Filion et al.,
1967). B. avium is an acute infectious pathogen that demonstrates high horizontal infectivity
and congenital transmissibility, and it mainly infects young chickens and turkeys (Beach et al.,
2012). This pathogen has been found in many other avian species, including Muscovy ducks,
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domesticated geese, partridges, ostriches, cockatoos, macaws,
parrot ﬁnches, and cockatiels (Hinz and Glunder, 1985; Raﬀel
et al., 2002). Widespread dissemination of this pathogen both
in wild and domesticated poultry was demonstrated by a
serum prevalence survey (Raﬀel et al., 2002). Harrington et al.
(2009) isolated a B. avium strain from patients with respiratory
diseases and proved that B. avium is also an opportunistic
pathogen in humans. The vaccines that are currently available to
prevent B. avium disease are mainly live, temperature-sensitive,
mutant vaccine, and whole-cell cephalosporins. Although the live
vaccines and bacterins of B. avium can provide protection to
at least 3-week-old turkeys, younger poultry respond poorly to
vaccination (Rimler and Kunkle, 1998). Existing vaccines can also
oﬀer some protection against severe diseases; however, they do
not limit the infection and spread of B. avium (Stockwell et al.,
2011). Developing a novel vaccine to prevent B. avium infection
is therefore necessary.
Since the ﬁrst DNA vaccine was reported in 1990 (Wolﬀ et al.,
1990), the eﬃcacy of DNA vaccines against infectious diseases
have been demonstrated (Robinson et al., 1993; Sun et al., 2010;
Borrego et al., 2011). Compared with the traditional inactivated,
attenuated, and subunit vaccines, DNA vaccines exhibit more
advantages by inducing a broad spectrum of cellular and humoral
immune responses. DNA vaccine immunization can prolong the
expression of antigens, as well as sustain their activity (Tang
et al., 1992; Yankauckas et al., 1993), which represents a novel
strategy to prevent or control some infectious diseases. Since
DNA vaccines have become popular during the past two decades,
this technology has brought both considerable excitement and
disappointment. The magnitude of immune responses elicited
by DNA vaccines are generally lower in humans and large
animals than in small animals, as proven by a number of
clinical trials (Laddy and Weiner, 2006). Therefore, further
development of DNA vaccines has been limited by their relatively
modest immunogenicity. To overcome this deﬁciency, several
strategies have been proposed to enhance the eﬃcacy of DNA
vaccines. Among these, applying an adjuvant in vaccination
is a good option to improve the immunogenicity of DNA
vaccines.
Adjuvants are believed to activate the innate immune
system, and thereby enhance the adaptive immune response
to a simultaneously administered antigen (O’Hagan and De
Gregorio, 2009; Mbow et al., 2010). Investigating novel plant
compounds that modulate the immune system have become a
promising ﬁeld of research, particularly in searching for new-
generation vaccine adjuvants (Licciardi and Underwood, 2011).
Many polysaccharides, such as Astragalus polysaccharides, Panax
ginseng polysaccharides, andGanoderma lucidum polysaccharide
F3, have been demonstrated their immunopotentiating function
and adjuvant eﬃcacy (Jiang et al., 2010; Lai et al., 2010; Ma et al.,
2010). Notably, pine pollen, a kind of nutritional pollen, which
is gloriously known as “King of Pollen” in China, has attracted
our attention. The principal pine species in Mount Taishan
region is Pinus massoniana, and the polysaccharides extracted
from Taishan Pinus massoniana pollen has been studied in our
laboratory since 2003, which has been found to be an eﬀective
adjuvant for inactivated and subunit vaccines (Wei et al., 2011;
Cui et al., 2013). However, the use of Taishan Pinus massoniana
pollen polysaccharides (TPPPS) as an adjuvant of DNA vaccines
has not yet been investigated.
In the current study, to develop a novel B. avium vaccine, we
constructed a recombinant plasmid expressing B. avium outer
membrane protein A (ompA), which is an important component
of the outer membrane protein and can induce high antibody
titers as a protective antigen (Gentry-Weeks et al., 1992). To
improve the immunogenicity of this DNA vaccine, TPPPS was
used as an adjuvant for the DNA vaccine to examine its immune
conditioning eﬀects. We found that the recombinant ompA-
DNA vaccine induced speciﬁc immune responses, although it
incompletely protected the chickens against B. avium challenge.
By contrast, the TPPPS adjuvant elevated the immune eﬀects of
the DNA vaccine to resist the B. avium challenge eﬀectively.
MATERIALS AND METHODS
Ethics Statement
The animal procedures used in this study were approved by
the Animal Care and Use Committee of Shandong Agricultural
University (Permit number: 20010510) and performed in
accordance with the “Guidelines for Experimental Animals” of
the Ministry of Science and Technology (Beijing, China).
Bacterial Strains, Plasmids, and Cells
Bordetella avium LL strain was isolated in our laboratory in 2008
(Shandong, China). The strain was cultured and maintained in
lysogeny broth agar and broth at 37◦C. The eukaryotic expression
plasmid pVAX1 was purchased from Invitrogen (Carlsbad, CA,
USA). In addition, BHK-21 cells were maintained in minimum
essential medium (MEM, GIBCO) that contained 10% fetal
bovine serum (FBS, GIBCO) and 1% antibiotics (Invitrogen) at
37◦C in a humidiﬁed atmosphere of 5% CO2.
Construction of Recombinant ompA
Plasmid
The primers were designed according to the ompA gene
sequence of B. avium (GenBank accession number: M96550.1)
using Primer 5.0. EcoR I and Xho I restriction enzyme sites
were introduced into the respective 5′ termini (underlined):
forward primer 5′-GCGAATTCCATGAACAAACCCTCCAA
A-3′ and reverse primer 5′-CCGCTCGAGTTACTTGCGGCTA
CCGACGATT-3′. The polymerase chain reaction (PCR) product
was digested with EcoR I and Xho I and cloned into the pVAX1
vector. The resultant plasmid was conﬁrmed by sequencing
(Sunny, Shanghai) and then transformed into DH5α competent
cells (E. coli) to amplify the yield.
Transfection and Western Blot Analysis
Conﬂuent BHK-21 cells were cultured in 6-well plates without
antibiotics, and recombinant ompA plasmids (4 μg) were
transfected into the BHK-21 cells using Lipofectamine
(Invitrogen). The transfected cells were cultured inMEMwith 1%
FBS for 72 h. The expressed ompA in the cell culture supernatants
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was puriﬁed through nickel aﬃnity chromatography according
to a previous method (Asgarian-Omran et al., 2013) and then
veriﬁed through Western blot analysis using an anti His-Tag
monoclonal antibody (Cwbio, China; Temple et al., 2010).
Vaccine Preparation
Taishan Pinus massoniana pollen polysaccharides was prepared
in our laboratory through water extraction and ethanol
precipitation (Wei et al., 2011). The recombinant plasmids in
E. coli DH5α were extracted using EndoFree Plasmid Giga
Kit (Qiagen). Plasmid concentration was determined using
NanoDrop (Thermo). The recombinant plasmids were then
mixed with TPPPS or Freund’s incomplete adjuvant (Solarbio,
Beijing) at a ratio of 1:1 up to a ﬁnal concentration of 250μg/mL.
The contents of TPPPS were set at three doses, namely, 50 (low),
100 (moderate), and 200 (high) mg/mL, in three separate TPPPS
adjuvant vaccines. The recombinant plasmids mixed with three
doses of TPPPS and Freund’s adjuvant were separately prepared
to obtain the corresponding adjuvant DNA vaccines.
Animal Experiment
A total of 224 one-day-old speciﬁc pathogen-free white leghorn
chickens (male; Spirax Ferrer Poultry Co., Ltd, Jinan) were
randomly separated into seven sterilized isolators, and each
isolator contained a group of 32 chickens (groups I–VII). The
ambient conditions were set to 20–25◦C and 30–40% relative
humidity, and the air entering the isolators was ﬁltered.
The chickens in groups I–VII were intramuscularly injected
with 0.4 mL low, moderate, and high doses TPPPS adjuvant
ompA-DNA vaccines, Freund’s adjuvant ompA-DNA vaccine,
pure ompA-DNA vaccine, empty plasmid, and phosphate
buﬀered saline (PBS), respectively, at 1, 7, and 14 days old.
Groups I–VII were named OmpA-TPPPS (L), OmpA-TPPPS
(M), OmpA-TPPPS (H), OmpA-Freund, OmpA, Empty plasmid,
and Mock, respectively. At 7, 14, 21, 28, 35, 42, and 49 days
post the ﬁrst inoculation (dpi), three chickens from each group
were selected randomly to determine the antibody, IFN-γ, IL-
2, and IL-4 concentrations in serum, as well as the CD4+ and
CD8+ T lymphocytes counts in peripheral blood. The animals
were starved for 12 h before sampling.
One week after the third inoculation (21 dpi), 20 chickens
in each group (including nine sampled and 11 unsampled
chickens) were placed into a new isolator and then challenged
intraperitoneally with 10 median lethal dose (LD50) B. avium LL
strain. Clinical symptoms, including labored breathing, sneezing,
and oculonasal discharges, were monitored for 7 days after
challenge. The protective rate in each group were calculated
according to the following formulas:
Protective rate (%) = No. of chickenswithout clinical symptoms
TotalNo. × 100% .
Detection of Serum Antibody Titers,
IFN-γ, IL-2, and IL-4
Three serum samples from each group were randomly collected
during sampling. The serum antibody titers were detected
via enzyme-linked immunosorbent assay (ELISA) as described
previously (Li et al., 2012). In addition, the cytokines of IFN-γ,
IL-2, and IL-4 were detected using the chicken IFN-γ, IL-2, and
IL-4 ELISA kits (Langdon Bio-technology Co., Ltd, Shanghai),
respectively. The absorbance at 450 nm was measured using an
ELISA reader.
Detection of CD4+ and CD8+ T
Lymphocytes in Peripheral Blood
Fresh, anticoagulant-treated peripheral blood samples from three
chickens in each group were randomly collected and separately
mixed with an equivalent volume of PBS. Then, 2 mL of the
mixture was added into 3 mL lymphocyte separation medium
(Solarbio, China), which was centrifuged at 2000 rpm for 15 min.
The lymphocytes were harvested and washed twice with PBS.
CD4+ dye (10 μL, Mouse Anti-chicken CD4-FITC, Cat: 8210-02,
Lot: H4809-MM62, USA) and CD8+ dye (10 μL, Mouse Anti-
chicken CD8-RPE, Cat: 8220-09, Lot: G149-VJ39K, USA) were
added into 50 μL lymphocyte suspension. The suspension was
incubated at 4◦C for 20 min. The percentages of CD4+ and CD8+
T lymphocytes were detected via ﬂow cytometry (Guaga Easy
Cyte Mini, USA).
Statistical Analysis
Data were presented as mean ± standard deviation (SD), and
Duncan’s multiple-range test was performed to analyze the
diﬀerences among groups using SPSS 17.0 software. A P-value of
<0.05 was considered statistically signiﬁcant.
RESULTS
Construction and Expression of
Recombinant ompA Plasmid
Firstly, the ompA gene of B. avium was ampliﬁed by PCR, and
agarose gel electrophoresis showed that the size of the ampliﬁed
ompA PCR products was 597 bp, which was consistent with
the expected ompA fragment size. Then the PCR products were
cloned into the pVAX1 vector, and the recombinant plasmid
was veriﬁed through restriction digestion and sequencing (data
not shown). After transfection into the BHK-21 cells, the
target recombinant protein was puriﬁed via nickel aﬃnity
chromatography based on the presence of 6× His tag in the
fusion protein. The contaminant proteins were washed with
buﬀer with 20 mM imidazole, and the target protein was eluted
with buﬀer that contained 0.5 M imidazole. The protein fractions
were analyzed via SDS-PAGE and Western blot analysis, and
the results showed that a single protein band with an apparent
molecular weight of 27 kDa was obtained after puriﬁcation
(Figure 1).
Changes in Serum Antibody Titers
The levels of antibody induced by vaccination are the key to
examining the eﬀects of vaccines. The dynamic changes in the
serum antibody titers in each group are presented in Figure 2.
At 14 dpi, the serum antibody titers in groups OmpA-TPPPS
(L), (M), (H), OmpA-Freund, and OmpA increased and were
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FIGURE 1 | SDS-PAGE (A) and Western blot (B) of the expressed ompA
in the supernatant. (A) M, protein molecular weight markers; lane 1,
proteins isolated from the culture supernatant of BHK-21 cells at 72 h after
empty plasmid transfection (negative control); lane 2, proteins isolated from
the culture supernatant of BHK-21 cells at 72 h after pVAX1-ompA plasmid
transfection. (B) M, PageRuler prestained protein ladder; 1, proteins isolated
from the culture supernatant of BHK-21 cells at 72 h after pVAX1-ompA
plasmid transfection; 2, purified recombinant protein from eluted fraction; 3,
proteins isolated from the culture supernatant of BHK-21 cells at 72 h after
empty plasmid transfection (negative control).
FIGURE 2 | Changes in the serum antibody titers of the chickens
inoculated with vaccines. Chickens in the seven groups were inoculated
with 50 (purple), 100 (blue), and 200 (red) mg/mL of TPPPS adjuvant
ompA-DNA vaccines, Freund’s adjuvant ompA-DNA vaccine (green), pure
ompA-DNA vaccine (cyan), empty plasmid (yellow), and PBS (black),
respectively, at 1, 7, and 14 days old. Serum was collected at 7, 14, 21, 28,
35, 42, and 49 dpi. The antibody titers were then determined via indirect
ELISA. All values shown are the means ± SD of three independent
experiments.
signiﬁcantly higher than those in groups Empty plasmid and
Mock (P < 0.05). Notably, the serum antibody titers in group
OmpA-TPPPS (H) were signiﬁcantly higher than those in other
groups (P < 0.05) at 14–49 dpi. At 35 dpi, the serum antibody
titers in groups OmpA-TPPPS (L), (M), (H), and OmpA-Freund
reached their peak value and were higher than those in group
OmpA. However, the antibody titers in group OmpA peaked at
42 dpi.
Changes in Serum IFN-γ, IL-2, and IL-4
Cytokines are crucial in ﬁghting oﬀ infections and are involved
in immune responses (Lowry, 1993). The results of serum IFN-γ,
IL-2, and IL-4 concentrations are shown in Figure 3. As shown
in Figures 3A,B, the serum IFN-γ and IL-2 concentrations
were signiﬁcantly higher in group OmpA than in groups Empty
plasmid and Mock (P < 0.05). Moreover, the concentrations of
these two cytokines were signiﬁcantly higher in groups OmpA-
TPPPS (L), (M), (H), and OmpA-Freund than in group OmpA
(P < 0.05), and these two indicators were signiﬁcantly higher
in group OmpA-TPPPS (H) than in other groups (P < 0.05).
As shown in Figure 3C, the concentrations of serum IL-
4 in group OmpA-TPPPS (H) were signiﬁcantly higher than
in other groups (P < 0.05). The overall IL-4 concentrations
in groups OmpA-TPPPS (L), (M), (H), and OmpA-Freund
were also signiﬁcantly higher than in groups OmpA, Empty
plasmid, and Mock (P < 0.05). A comparison between group
OmpA and groups Empty plasmid and Mock indicated that the
serum IL-4 concentrations were higher in group OmpA than in
groups Empty plasmid and Mock, although the disparity was
insigniﬁcant (P > 0.05).
Changes in CD4+ and CD8+ T
Lymphocyte Counts in the Peripheral
Blood
CD4+ and CD8+ T lymphocyte counts directly reﬂect immune
function in animals (Torti et al., 2012). Tables 1 and 2 show
the percentages of CD4+ and CD8+ T lymphocytes in the
peripheral blood, respectively, where the percentages of CD4+
and CD8+ T lymphocytes were signiﬁcantly higher in group
OmpA than in groups Empty plasmid and Mock (P < 0.05).
Moreover, the percentages of CD4+ and CD8+ T lymphocytes
in groups OmpA-TPPPS (L), (M), (H), and OmpA-Freund were
signiﬁcantly higher than those in group OmpA (P < 0.05).
Notably, The percentages of CD4+ and CD8+ T lymphocytes
were also signiﬁcantly higher in group OmpA-TPPPS (H) than
in other groups (P < 0.05).
Protective Effects of the Vaccines
To evaluate the protective eﬀects of the ompA-DNA vaccine
against B. avium infection, we challenged 20 chickens from
each group with 10 LD50 B. avium LL strain at 1 week post
the third inoculation. Clinical symptoms were monitored daily,
and the protective rates of diﬀerent groups were calculated as
described in the section “Materials and Methods” (Figure 4).
The result showed that the morbidity was signiﬁcantly lower
in chickens inoculated with the ompA-DNA vaccine than in
chickens in the groups Empty plasmid and Mock (P < 0.05).
In addition, the protective rate in group OmpA-TPPPS (H)
was signiﬁcantly higher than those in other groups (P < 0.05).
These data demonstrated that the pure ompA-DNA vaccine could
protect the chickens against B. avium infection at a rate of 50%,
and the ompA-DNA vaccine with 200 mg/mL TPPPS completely
protected the chickens against B. avium infection.
DISCUSSION
Bordetella avium is the causative agent of a highly contagious
upper respiratory disease in young poultry, and existing
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FIGURE 3 | Changes in cytokines in the chickens inoculated with vaccines. Chickens in the seven groups were inoculated with 50 (purple), 100 (blue), and
200 (red) mg/mL of TPPPS adjuvant ompA-DNA vaccines, Freund’s adjuvant ompA-DNA vaccine (green), pure ompA-DNA vaccine (cyan), empty plasmid (yellow),
and PBS (black), respectively, at 1, 7, and 14 days old. Serum was collected at 7, 14, 21, 28, 35, 42, and 49 dpi. IFN-γ (A), IL-2 (B), and IL-4 (C) were detected
using the chicken IFN-γ, IL-2, and IL-4 ELISA kits. All values shown are the means ± SD of three independent experiments.
vaccines provide limited protection only. In this study, we
constructed a recombinant plasmid that expressed B. avium
ompA, which was used to prepare a novel B. avium DNA
vaccine. In addition, TPPPS was used as the adjuvant of
this DNA vaccine, and its immune conditioning eﬀects were
examined. We determined that the pure ompA-DNA vaccine
induced speciﬁc immune responses and protected the chickens,
which displayed a 50% protective rate. By contrast, the
TPPPS adjuvant ompA-DNA vaccine elicited remarkably higher
levels of serum antibody titers, cytokines, and T lymphocyte
counts, as well as caused higher protective rates among the
chickens.
TABLE 1 | Changes of CD4+ T lymphocyte counts in peripheral blood.
Group∗ Days post the first inoculation (d)#
7 14 21 28 35 42 49
OmpA-TPPPS (L) 7.26 ± 0.83a 8.81 ± 0.61a 11.33 ± 0.63a 13.25 ± 1.13a 14.49 ± 0.42a 15.76 ± 0.35a 14.67 ± 1.02a
OmpA-TPPPS (M) 9.11 ± 0.93b 12.44 ± 0.81b 15.84 ± 0.78b 17.45 ± 0.99b 18.33 ± 0.79b 20.26 ± 0.85b 17.65 ± 0.74b
OmpA-TPPPS (H) 11.70 ± 0.06c 15.38 ± 0.45c 18.83 ± 0.47c 22.04 ± 0.49c 24.29 ± 0.67c 27.98 ± 1.05c 25.32 ± 0.80c
OmpA-Freund 9.84 ± 0.41b 13.00 ± 0.80b 15.59 ± 0.79b 18.00 ± 0.90b 18.66 ± 0.11b 19.59 ± 0.62b 17.00 ± 0.80b
OmpA 5.00 ± 0.90d 6.26 ± 0.86d 8.18 ± 0.75d 10.36 ± 0.79d 11.28 ± 0.10d 12.30 ± 0.10d 10.01 ± 0.69d
Empty plasmid 4.40 ± 0.60d 5.00 ± 0.10e 6.00 ± 0.90e 7.37 ± 0.15e 6.99 ± 0.55e 7.24 ± 0.70e 6.72 ± 0.24e
Mock 4.30 ± 0.30d 5.00 ± 0.40e 5.00 ± 0.50e 7.41 ± 0.71e 6.52 ± 0.42e 6.38 ± 0.13e 6.44 ± 0.11e
∗Group names represent that chickens in these groups were inoculated with 50, 100, and 200 mg/mL of TPPPS adjuvant ompA-DNA vaccines, Freund’s adjuvant
ompA-DNA vaccine, pure ompA vaccine, empty plasmid, and PBS, respectively.
#CD4+ T lymphocyte counts in the same column are compared by Duncan’s multiple-range tests. Different lowercase letter superscripts indicate significant differences
(P<0.05). Data are expressed as mean percentage ± SD.
TABLE 2 | Changes of CD8+ T lymphocyte counts in peripheral blood.
Group∗ Days post the first inoculation (d)#
7 14 21 28 35 42 49
OmpA-TPPPS (L) 5.56 ± 0.86a 7.23 ± 0.21a 9.26 ± 0.69a 10.26 ± 0.55a 11.18 ± 0.33a 13.31 ± 0.38a 12.01 ± 0.12a
OmpA-TPPPS (M) 7.03 ± 0.20b 8.00 ± 0.55a 10.60 ± 0.35b 12.00 ± 0.50b 14.00 ± 0.70b 16.03 ± 0.35b 14.87 ± 0.61b
OmpA-TPPPS (H) 8.03 ± 0.45c 10.00 ± 0.40b 12.29 ± 0.27c 14.10 ± 0.38c 16.37 ± 0.75c 17.94 ± 0.83c 16.82 ± 0.87c
OmpA-Freund 7.97 ± 0.25c 9.00 ± 0.60c 11.00 ± 0.90b 12.93 ± 0.40b 14.00 ± 0.30b 15.00 ± 0.50d 13.10 ± 0.10d
OmpA 4.99 ± 0.02a 5.98 ± 0.90d 6.66 ± 0.87d 7.95 ± 0.83d 9.00 ± 0.50d 11.00 ± 0.60e 8.02 ± 0.67e
Empty plasmid 4.18 ± 0.35d 4.96 ± 0.44e 5.39 ± 0.30e 5.96 ± 0.48e 5.75 ± 0.40e 5.38 ± 0.39f 5.65 ± 0.48f
Mock 4.23 ± 0.32d 4.70 ± 0.34e 5.42 ± 0.42e 5.94 ± 0.48e 5.78 ± 0.36e 5.58 ± 0.38f 5.58 ± 0.02f
∗Group names represent that chickens in these groups were inoculated with 50, 100, and 200 mg/mL of TPPPS adjuvant ompA-DNA vaccines, Freund’s adjuvant
ompA-DNA vaccine, pure ompA vaccine, empty plasmid, and PBS, respectively.
#CD8+ T lymphocyte counts in the same column are compared by Duncan’s multiple-range tests. Different lowercase letter superscripts indicate significant differences
(P < 0.05). Data are expressed as mean percentage ± SD.
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FIGURE 4 | Protective rates of B. avium-challenged chickens.
Chickens in the seven groups were inoculated with 50 (purple), 100
(blue), and 200 (red) mg/mL of TPPPS adjuvant ompA-DNA vaccines,
Freund’s adjuvant ompA-DNA vaccine (green), pure ompA-DNA vaccine
(cyan), empty plasmid (yellow), and PBS (black), respectively, at 1, 7,
and 14 days old. One week after the third inoculation, 20 chickens from
each group were challenged intraperitoneally with 10 LD50 B. avium LL
strain. Clinical symptoms, including labored breathing, sneezing, and
oculonasal discharges, were monitored for seven successive days after
the challenge.
DNA vaccine, also known as nucleic acid vaccine, is a new
research ﬁeld that has been developed in the research of gene
therapy in recent years. DNA vaccine can express antigen protein
via eukaryotic expression pattern when it is absorbed by the host
cells; the sustained expression can induce a strong and lasting
immune response in vertebrates. In this study, the natural ompA
of B. avium is a prokaryotic protein, and its molecular structure
may become more complex when it is expressed in the eukaryotic
expression system. Thus, some epitopes may be altered or hidden.
However, our results have proven that the ompA expressed in
host cells also provided a certain immune protection, thereby
indicating that it retained certain epitopes and immunogenicity
of natural ompA. Moreover, we found that the addition of TPPPS
adjuvant remarkably improved the immune protective eﬀects
of ompA-DNA vaccine. This result further veriﬁed the speciﬁc
antigenicity of ompA and implied the immunoregulatory activity
of TPPPS.
DNA vaccine oﬀers distinctive advantages compared with
traditional vaccines. This type of vaccine promotes the expression
of speciﬁc antigens in host cells and elicits both humoral and
cellular immune responses. In addition, it is easy to produce,
relatively inexpensive, homogeneous and heat stable (Belakova
et al., 2007). However, given that the immune response of DNA
vaccines depends on several parameters, such as the selection
of the candidate antigen, vaccine vector, adjuvant type, and
administration route (Oran and Robinson, 2003; Perrie et al.,
2003; Sasaki et al., 2003; Liu, 2011), all of these factors may
possibly inﬂuence the eﬀects of vaccination. The safety of
using vaccine vectors in animals is a primary consideration.
This study employed the pVAX1 plasmid, the use of which
was approved by the US Food and Drug Administration
(“Points to Consider on Plasmid DNA Vaccines for Preventive
Infectious Disease Indications,” published on December 22,
1996, Docket No. 96N-0400). To date, the pVAX1 plasmid
is the safest vector in DNA vaccine, because it demonstrates
minimal possibility of chromosomal integration and is less
likely to elicit allergic responses. Studies have reported that
pure pVAX1 plasmid does not exert any negative eﬀect on
animals and does not interfere with the eﬃcacy of DNA
vaccines (Song et al., 2009, 2010), which is consistent with our
results. Moreover, we chose traditional intramuscular injection
as the inoculation method in our animal experiment. Some
studies, however, have shown that inoculation via electroporation
can enhance plasmid uptake and immune responses (Bodles-
Brakhop and Draghia-Akli, 2008). Many novel DNA delivery
systems have also been invented, including gene gun and
synthetic delivery systems. Thus, further studies must investigate
the eﬀects of the ompA-DNA vaccine using novel delivery
systems.
Two types of T helper (Th) clones (Th1 and Th2 cells) diﬀer
in cytokine secretion patterns and in other functions (Mosmann
et al., 1986). The major cytokines associated with the Th1
cell subsets are IL-2, TNF-α, and IFN-γ, which can enhance
Tc cellular cytotoxicity and cell-mediated immune responses.
The Th2 cell subsets secrete IL-4, IL-5, and IL-10, and these
cytokines mainly promote antibody production and mediate
humoral immune responses. We observed that the ompA-
DNA vaccine signiﬁcantly enhanced the production of IFN-γ
and IL-2, but not IL-4, which indicated that the ompA-DNA
vaccine mainly induced Th1 immune response. In antibacterial
defense, these Th1 cytokines may enhance the proliferation
and diﬀerentiation of lymphocytes and bactericidal activities
of the innate immune cells, such as nature killer cells and
macrophages.
Adjuvants are widely applied to improve the immunogenicity
of subunit virus-like particles and DNA vaccines (Buonaguro
et al., 2011). Various plant polysaccharides, such as
Astragalus, Panax ginseng, and Taishan Robinia pseudoacacia
polysaccharides, cannot only activate immunocytes but can
also improve cytokine secretion (Jiang et al., 2010; Ma et al.,
2010; Zhang et al., 2014). They also activate complement and
reticuloendothelial systems, thereby regulating the immunologic
function of organisms (Currier et al., 2003; Lai et al., 2010).
Moreover, plant polysaccharides are typically less immunogenic,
non-toxic, and biodegradable, and thus, are considered novel
natural immune potentiator. Our previous studies have revealed
that TPPPS can signiﬁcantly strengthen immune response and
enhance the eﬀects of vaccines (Wei et al., 2011; Cui et al.,
2013). In addition, TPPPS is water-soluble and exhibits high
hydrophilicity and viscidity, which are suitable properties for
an adjuvant (Wei et al., 2011). The present study showed that
the chickens inoculated with the TPPPS adjuvant ompA-DNA
vaccine displayed higher immunity and protective rate than
those inoculated with the pure ompA-DNA vaccine. Notably,
the 200 mg/mL TPPPS exhibited the best capability to improve
the eﬀects of the ompA-DNA vaccine. TPPPS also shortened
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the time before antibody levels peaked. Therefore, TPPPS is a
potential vaccine adjuvant.
CONCLUSION
This study demonstrated that the ompA-DNA vaccine induced
both humoral and cellular immune responses (particularly
the Th1 type). TPPPS, which was used as the adjuvant,
eﬀectively improved the immunogenicity of DNA vaccine,
including antibody production, cytokine secretion, lymphocyte
diﬀerentiation, and protective rate. The results of this study
indicated the potential of the B. avium ompA-DNA vaccine
combined with TPPPS adjuvant in preventing B. avium infection.
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